Table 5.

Mortality risk in SLS II patients as a function of baseline neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio

	Neutrophil		Lymphocyte		NLR*
Characteristic	HR [95% CI]	P-value	HR [95% CI]	P-value	HR [95% CI]	P-value
Baseline count or ratio	2.22 [1.02, 4.80]	0.044	0.50 [0.23, 1.07]	0.075	1.84 [1.17, 2.91]	0.009
Age at enrollment	1.08 [1.03, 1.14]	0.001	1.09 [1.03, 1.14]	0.001	1.08 [1.03, 1.13]	0.002
Treatment arm†	0.94 [0.41, 2.14]	0.880	0.85 [0.36, 2.01]	0.719	0.82 [0.35, 1.91]	0.646

Analysis by multivariable Cox proportional hazards model

^*Neutrophil-to-lymphocyte ratio

^†Mycophenolate compared to cyclophosphamide treatment groups